XERS Q3 2024 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M+12.3% YoY

Gross Profit

$41M75.0% margin

Operating Income

-$13M-23.8% margin

Net Income

-$16M-29.0% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+12.9%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$321M

Total Liabilities

$349M

Stockholders' Equity

-$28M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$48M	+12.3%
Gross Profit	$41M	$40M	+1.4%
Operating Income	-$13M	-$5M	-162.4%
Net Income	-$16M	-$12M	-29.1%

Revenue Segments

Product

$53M81%

Keveyis

$12M19%